Vimarsana
Biggest News Aggregation in the World

Stroke Statistics Subcommittee News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Stroke Statistics Subcommittee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Stroke Statistics Subcommittee Today - Breaking & Trending Today

Heart Disease Reigns as Top Killer, but Many Don't Know It - Vimarsana News

Heart Disease Reigns as Top Killer, but Many Don't Know It

CVD is blamed for 27% of deaths globally, but 51% of AHA survey respondents didn’t know it was the leading cause of death.

Source: tctmd.com
The Top Killer Is Heart Disease, But Many Don't Know About It - Vimarsana News

The Top Killer Is Heart Disease, But Many Don't Know About It

(CTN News) - Americans are not aware that heart disease is the leading cause of death around the world, according to new data from..............

Heart Disease Still the Leading Cause of Death in the US - Vimarsana News

Heart Disease Still the Leading Cause of Death in the US

Death rates from cardiovascular disease have fluctuated over the years and trended upward recently.

Source: empr.com
Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023 - Vimarsana News

Positive Results from ReVeRA Phase 2 Study of Etripamil Nasal Spray in AFib-RVR Presented by Milestone Pharmaceuticals during AHA 2023

Milestone Pharmaceuticals Inc. recently announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in patients with atrial fibrillation with rapid ventricular rate (AFib-RVR) compared to placebo. The findings were presented during the American Heart Association Scientific Sessions 2023, held recently in Philadephia, PA.

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 - Vimarsana News

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Etripamil, an investigational drug, showed statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate  compared to...